SCHEMBL13020174

SCHEMBL13020174

CC(C)(C)n1cc(-c2ccc(Cl)cc2)c2c(NC(=O)C3CCCO3)ncnc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 2/20 0.50
LCK P06239 1/20 0.50
KDR P35968 1/20 0.50
TEK Q02763 1/20 0.50
RAB9A P51151 3/20 0.46
ALDH1A1 P00352 6/20 0.43
KDM4E B2RXH2 4/20 0.43
HTT P42858 2/20 0.43
HPGD P15428 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
NPC1 O15118 2/20 0.42
MAPT P10636 1/20 0.42
HSD17B10 Q99714 4/20 0.42
ALOX15 P16050 1/20 0.41
LMNA P02545 2/20 0.40
TSHR P16473 1/20 0.40
CLK1 P49759 1/20 0.39
MAPK1 P28482 2/20 0.39
WNT1 P04628 1/20 0.39
GSK3B P49841 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13020105 0.86 KDR (0.54) SRCLCKKDRTEKALDH1A1
SCHEMBL13020194 0.86 KDR (0.54) SRCLCKKDRTEKRAB9A
SCHEMBL13020347 0.86 KDR (0.56) SRCLCKKDRTEKALDH1A1
SCHEMBL13020176 0.84 KDR (0.50) SRCLCKKDRTEKALDH1A1
SCHEMBL13020202 0.81 KDR (0.55) SRCLCKKDRTEKALDH1A1
SCHEMBL13020173 0.81 KDM4E (0.63) SRCLCKKDRTEKALDH1A1
SCHEMBL13020179 0.80 KDR (0.50) SRCLCKKDRTEKALDH1A1
SCHEMBL13020138 0.80 LCK (0.61) SRCLCKKDRTEKALDH1A1
SCHEMBL13840229 0.78 LCK (0.56) SRCLCKKDRTEKALDH1A1
SCHEMBL13020123 0.78 LCK (0.58) SRCLCKKDRTEKALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B SRC 1332/4885LCK 1980/4885KDR 4598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.